CSIMarket


Atossa Therapeutics Inc   (ATOS)
Other Ticker:  
 


 

Atossa Therapeutics Inc

ATOS's Financial Statements and Analysis



Atossa Therapeutics Inc narrowed third quarter of 2023 net loss per share of $-0.05 compare to net loss per share of $-0.06 recorded in the same quarter a year ago and improved compare to net loss per share of $-0.08 realized in previous quarter.


third quarter of 2023
Earnings Per Share Revenues
$ -0.05 $  0 Mill
$+0.01     Unch.    



Atossa Therapeutics Inc 's Revenue fell by 0 % in third quarter of 2023 (Sep 30 2023) year on year, to $0 million and declined by sequentially.


Atossa Therapeutics Inc is

More on ATOS's Income Statement



Atossa Therapeutics Inc 's in thethird quarter of 2023 recorded net loss of $-6.229 million, an improvement compare to net loss of $-8.011 million in III. Quarter a year ago.

Sequentially net loss narrowed from net loss of $-9.830 million realized in previous quarter.

More on ATOS's Growth

Atossa Therapeutics Inc Inventories
In Sep 30 2023 company's net cash and cash equivalents decreased by $-17 million

More on ATOS's Cash flow Statement


Atossa Therapeutics Inc does not pay out common stock dividend.

In trailing twelve-month period Atossa Therapeutics Inc payed $ -0.16 cash per share, on a free-cash flow basis .

Book value fell by -5.70 % sequentially to $0.78 per share, -19.74% of net loss per share in trailing twelve-month period were subtructed from shareholder value.
Tangible Book value fell to $ 0.78 per share from $ 0.82.

Company repurchased 0.83 million shares or 0.66 % in Sep 30 2023.


More on ATOS's Dividends

 Market Capitalization (Millions) 226
 Shares Outstanding (Millions) 126
 Total Debt (Millions $) -
 Revenue (TTM) (Millions $) -
 Net Income (TTM) (Millions $) -30
 Cash Flow (TTM) (Millions $) -42
 Capital Exp. (TTM) (Millions $) 0
 Dividend TTM ($) 0 $
 Dividend Yield TTM (%) -
 Employees (TTM) $ 9




Atossa Therapeutics Inc does not pay out common stock dividend.

In trailing twelve-month period Atossa Therapeutics Inc had negative $ -0.16 cash flow per share, on a free-cash flow basis .

Book value fell by -5.70 % sequentially to $0.78 per share, -19.74% of net loss per share in trailing twelve-month period were subtructed from shareholder value.
Tangible Book value fell to $ 0.78 per share from $ 0.82.

Company repurchased 0.83 million shares or 0.66 % in Sep 30 2023.


More on ATOS's Balance Sheets

 Market Capitalization (Millions) 226
 Shares Outstanding (Millions) 126
 Total Debt (Millions $) -
 Revenue (TTM) (Millions $) -
 Net Income (TTM) (Millions $) -30
 Cash Flow (TTM) (Millions $) -42
 Capital Exp. (TTM) (Millions $) 0
 Dividend TTM ($) 0 $
 Dividend Yield TTM (%) -
 Employees (TTM) $ 9
   


  News about Atossa Therapeutics Inc Earnings

Revamping the Headline for Atossa Therapeutics Inc: Pioneering Biotech Firm Atossa Therapeutics Inc. Records Operating Deficit in Q3 2023

Atossa Therapeuti...

ATOS Releases Second Quarter 2023 Results with Operating Deficit of $-7.793 million; Shareholders Awaiting Future Business Strategy

The Major Pharmaceutical Preparations industry has been closely watched during the ongoing earnings season, with several businesses within the sector releasing their financial results. One such company is ATOS, which recently announced an operating deficit of $-7.793 million for the fiscal period ending on June 30, 2023.
Shareholders of ATOS are eagerly awaiting the release of the company's future business strategy, hoping for a turnaround in their financial performance. While the current organizational and operational excellence of Atossa Therapeutics Inc may not be of significant interest to stakeholders at this time, they understand that businesses often go through challenging periods as they strive t...


Date modified: 2023-11-13T23:55:37+00:00





Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com